Laura MacPherson

Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses

Kah Lok Chan, Juliana Gomez, Chelisa Cardinez, Nishi Kumari, Christina E Sparbier, Enid YN Lam, Miriam M Yeung, Sylvain Garciaz, James A Kuzich, Doen Ming Ong, Fiona C Brown, Yih-Chih Chan, Dane Vassiliadis, Elanor N Wainwright, Ali Motazedian, Andrea Gillespie, Katie A Fennell, Junyun Lai, Imran G House, Laura Macpherson, et al.

Journal article  |  2022  |  CANCER CELL

There is increasing recognition of the prognostic significance of tumor cell major histocompatibility complex (MHC) class II expre..

Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK Dependent Cell Death

Sylvain Garciaz, Andrew A Guirguis, Sebastian Muller, Fiona C Brown, Yih-Chih Chan, Ali Motazediani, Caitlin L Rowe, James A Kuzich, Kah Lok Chan, Kevin Tran, Lorey Smith, Laura MacPherson, Brian Liddicoat, Enid YN Lam, Tatiana Caneque, Marian L Burr, Veronique Litalien, Giovanna Pomilio, Mathilde Poplineau, Estelle Duprez, et al.

Journal article  |  2022  |  CANCER DISCOVERY

UNLABELLED: Cancer cell metabolism is increasingly recognized as providing an exciting therapeutic opportunity. However, a drug th..

Non-genetic determinants of malignant clonal fitness at single-cell resolution

Katie A Fennell, Dane Vassiliadis, Enid YN Lam, Luciano G Martelotto, Jesse J Balic, Sebastian Hollizeck, Tom S Weber, Timothy Semple, Qing Wang, Denise C Miles, Laura MacPherson, Yih-Chih Chan, Andrew A Guirguis, Lev M Kats, Emily S Wong, Sarah-Jane Dawson, Shalin H Naik, Mark A Dawson

Journal article  |  2021  |  NATURE

All cancers emerge after a period of clonal selection and subsequent clonal expansion. Although the evolutionary principles impart..

Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax

Sylvain Garciaz, Sebastian Muller, Andew Guirguis, Fiona C Brown, Yih Chih Chan, Mathilde Paplineau, Kevin Tran, Kah-Lok Chan, Laura Mac Pherson, Brian Liddicoat, Enid YN Lam, Tatiana Caneque, Marian L Burr, Veronique Litalien, Giovanna Pomilio, Estelle Duprez, David CS Huang, Sarah-Jane Dawson, Georg Ramm, Andrew G Cox, et al.

Conference Proceedings  |  2021  |  BLOOD

Abstract Although the BCL2 inhibitor venetoclax have been transformative in the management of AML, therapeutic resi..

First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER plus breast cancer with KAT6A dysregulation.

Shikhar Sharma, Jay Chung, Sean Uryu, Amanda Rickard, Natalie Nady, Showkhin Khan, Zhenxiong Wang, Yong Zhang, Haikuo Zhang, Pei-Pei Kung, Eric Greenwald, Karen Maegley, Patrick Bingham, Hieu Lam, Ylva E Bozikis, Hendrik Falk, Elizabeth Allan, Vicky M Avery, Miriam S Butler, Michelle A Camerino, et al.

Conference Proceedings  |  2021  |  CANCER RESEARCH

Abstract KAT6A is a lysine histone acetyltransferase (HAT) of the MYST family of HATs. KAT6A, and its paralog KAT6B..

Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models

Emma Morrish, Anthony Copeland, Donia M Moujalled, Jason A Powell, Natasha Silke, Ann Lin, Kate E Jarman, Jarrod J Sandow, Gregor Ebert, Liana Mackiewicz, Jessica A Beach, Elizabeth L Christie, Alexander C Lewis, Giovanna Pomilio, Karla C Fischer, Laura MacPherson, David DL Bowtell, Andrew Webb, Marc Pellegrini, Mark A Dawson, et al.

Journal article  |  2020  |  BLOOD ADVANCES

The specific targeting of inhibitor of apoptosis (IAP) proteins by Smac-mimetic (SM) drugs, such as birinapant, has been tested in..

HBO1 is required for the maintenance of leukaemia stem cells

Laura MacPherson, Juliana Anokye, Miriam M Yeung, Enid YN Lam, Yih-Chih Chan, Chen-Fang Weng, Paul Yeh, Kathy Knezevic, Miriam S Butler, Annabelle Hoegl, Kah-Lok Chan, Marian L Burr, Linden J Gearing, Tracy Willson, Joy Liu, Jarny Choi, Yuqing Yang, Rebecca A Bilardi, Hendrik Falk, Nguyen Nghi, et al.

Journal article  |  2020  |  NATURE

Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by transcriptional dysregulation that results in a block in..

Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia

Charles C Bell, Katie A Fenne, Yih-Chih Chan, Florian Rambow, Miriam M Yeung, Dane Vassiliadis, Luis Lara, Paul Yeh, Luciano G Martelotto, Aljosja Rogiers, Brandon E Kremer, Olena Barbash, Helai P Mohammad, Timothy M Johanson, Marian L Burr, Arindam Dhar, Natalie Karpinich, Luyi Tian, Dean S Tyler, Laura MacPherson, et al.

Journal article  |  2019  |  NATURE COMMUNICATIONS

Non-genetic drug resistance is increasingly recognised in various cancers. Molecular insights into this process are lacking and it..

Characterization of TCDD-inducible poly-ADP-ribose polymerase (TIPARP/ARTD14) catalytic activity

Alvin Gomez, Christian Bindesboll, Somisetty V Satheesh, Giulia Grimaldi, David Hutin, Laura MacPherson, Shaimaa Ahmed, Laura Tamblyn, Tiffany Cho, Hilde Irene Nebb, Anders Moen, Jan Haug Anonsen, Denis M Grant, Jason Matthews

Journal article  |  2018  |  BIOCHEMICAL JOURNAL

Here, we report the biochemical characterization of the mono-ADP-ribosyltransferase 2,3,7,8-tetrachlorodibenzo-p-dioxin poly-ADP-r..

Survival of the Fittest: Darwinian Selection Underpins Chemotherapy Resistance in AML

Laura MacPherson, Mark A Dawson

Journal article  |  2017  |  CELL STEM CELL

Intratumor heterogeneity driving therapeutic resistance is a major challenge in cancer management. Recently in Nature, Shlush et a..